Parkman Healthcare Partners LLC Takes $4.84 Million Position in Vir Biotechnology, Inc. $VIR

Posted by Stanley Muller on Aug 25th, 2026

Parkman Healthcare Partners LLC acquired a new stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) during the second quarter, Holdings Channel reports. The firm acquired 475,279 shares of the company’s stock, valued at approximately $4,843,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Pictet Asset Management Holding SA lifted its holdings in shares of Vir Biotechnology by 10,878.9% in the first quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company’s stock valued at $13,268,000 after buying an additional 1,467,340 shares during the period. Candriam S.C.A. grew its holdings in Vir Biotechnology by 10.1% during the first quarter. Candriam S.C.A. now owns 1,135,763 shares of the company’s stock worth $10,176,000 after acquiring an additional 104,100 shares during the period. UBS Group AG grew its holdings in Vir Biotechnology by 94.6% during the fourth quarter. UBS Group AG now owns 417,965 shares of the company’s stock worth $2,520,000 after acquiring an additional 203,203 shares during the period. Avidity Partners Management LP bought a new stake in Vir Biotechnology in the first quarter worth about $8,512,000. Finally, OP Asset Management Ltd bought a new stake in Vir Biotechnology in the first quarter worth about $1,013,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Vir Biotechnology Stock Up 1.3%

Shares of Vir Biotechnology stock opened at $9.91 on Tuesday. Vir Biotechnology, Inc. has a 12-month low of $4.35 and a 12-month high of $11.66. The firm has a market capitalization of $1.68 billion, a PE ratio of -5.33 and a beta of 1.66. The stock’s fifty day moving average is $9.44 and its 200-day moving average is $9.21.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.14. The business had revenue of $238.95 million during the quarter, compared to analyst estimates of $135.88 million. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.Vir Biotechnology’s revenue for the quarter was up 19582.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.80) EPS. Analysts expect that Vir Biotechnology, Inc. will post -1.84 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on VIR. Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Morgan Stanley set a $25.00 target price on shares of Vir Biotechnology in a report on Thursday, August 6th. HC Wainwright reissued a “buy” rating on shares of Vir Biotechnology in a research note on Monday, August 10th. Leerink Partners raised their target price on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.62.

View Our Latest Report on VIR

Insider Buying and Selling

In other Vir Biotechnology news, Director Janet Napolitano sold 3,200 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.45, for a total value of $30,240.00. Following the completion of the transaction, the director directly owned 21,216 shares in the company, valued at $200,491.20. This trade represents a 13.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.90% of the company’s stock.

About Vir Biotechnology

(Free Report)

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.